ACA
ABBV icon

Aptus Capital Advisors’s AbbVie ABBV Stock Holding History

Aptus Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3M Sell
134,719
-2,786
-2% -$618K 0.23% 87
2025
Q4 		$31.4M Buy
137,505
+2,358
+2% +$537K 0.23% 88
2025
Q3 		$31.3M Sell
135,147
-1,298
-1% -$264K 0.23% 84
2025
Q2 		$25.3M Buy
136,445
+13,171
+11% +$2.45M 0.21% 102
2025
Q1 		$25.8M Buy
123,274
+9,959
+9% +$1.94M 0.27% 81
2024
Q4 		$20.1M Buy
113,315
+29,972
+36% +$5.51M 0.21% 104
2024
Q3 		$16.5M Buy
83,343
+14,457
+21% +$2.7M 0.25% 97
2024
Q2 		$11.8M Buy
68,886
+13,887
+25% +$2.3M 0.21% 100
2024
Q1 		$10M Buy
54,999
+4,673
+9% +$805K 0.19% 104
2023
Q4 		$7.8M Sell
50,326
-4,844
-9% -$706K 0.21% 100
2023
Q3 		$8.22M Buy
55,170
+874
+2% +$128K 0.22% 91
2023
Q2 		$7.32M Sell
54,296
-12,873
-19% -$1.89M 0.18% 112
2023
Q1 		$10.7M Buy
67,169
+3,705
+6% +$566K 0.29% 73
2022
Q4 		$10.3M Buy
63,464
+7,903
+14% +$1.21M 0.31% 66
2022
Q3 		$7.46M Sell
55,561
-17,458
-24% -$2.51M 0.18% 76
2022
Q2 		$11.2M Buy
73,019
+26,921
+58% +$4.11M 0.29% 50
2022
Q1 		$7.47M Sell
46,098
-5,295
-10% -$769K 0.19% 79
2021
Q4 		$6.96M Buy
51,393
+7,113
+16% +$840K 0.21% 67
2021
Q3 		$4.78M Buy
44,280
+8,773
+25% +$1M 0.12% 88
2021
Q2 		$4M Buy
35,507
+4,494
+14% +$506K 0.12% 93
2021
Q1 		$3.36M Buy
31,013
+814
+3% +$87.1K 0.12% 94
2020
Q4 		$3.24M Sell
30,199
-263
-0.9% -$25.3K 0.15% 92
2020
Q3 		$2.67M Buy
30,462
+1,165
+4% +$110K 0.14% 91
2020
Q2 		$2.88M Buy
29,297
+1,608
+6% +$142K 0.18% 78
2020
Q1 		$2.11M Sell
27,689
-28,602
-51% -$2.44M 0.18% 93
2019
Q4 		$4.98M Buy
56,291
+8,022
+17% +$666K 0.35% 49
2019
Q3 		$3.65M Buy
48,269
+28,501
+144% +$1.95M 0.2% 49
2019
Q2 		$1.44M Buy
19,768
+306
+2% +$24.1K 0.2% 94
2019
Q1 		$1.57M Buy
19,462
+1,250
+7% +$102K 0.27% 92
2018
Q4 		$1.68M Buy
+18,212
New +$1.6M 0.44% 20

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aptus Capital Advisors's ABBV Position: Q1 2026 in Review

Aptus Capital Advisors reduced its AbbVie (ABBV) stake by 2% in Q1 2026, selling an estimated $618K and leaving 134,719 shares worth $29.3M. The position accounts for 0.23% of the portfolio, ranked #87.

Aptus Capital Advisors first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $31.4M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Aptus Capital Advisors held 134,719 shares of AbbVie worth $29.3M as of Q1 2026.
  • Aptus Capital Advisors sold 2,786 AbbVie shares in Q1 2026, an estimated $618K.
  • AbbVie made up 0.23% of Aptus Capital Advisors's portfolio in Q1 2026, its #87 holding.
  • Aptus Capital Advisors first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Aptus Capital Advisors's AbbVie position peaked at $31.4M in Q4 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.